ArticleDiagnostics (Basel, Switzerland)2021
PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- SpecificTheranostics · 2026Article
- Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Dependence of Renal Uptake on Kidney Function in [Diagnostics (Basel, Switzerland) · 2024Article
- PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches.Biomedicines · 2023Article
- High Prognostic Value ofDiagnostics (Basel, Switzerland) · 2023Article
- Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging.Clinical and translational radiation oncology · 2023Article
- The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review.Cancers · 2023Review
- PSMA-targeted therapy for non-prostate cancers.Frontiers in oncology · 2023Review
- Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma.European urology open science · 2022Article
- PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?Cancers · 2022Review
- Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.Journal of cancer research and clinical oncology · 2022Review
- Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.European urology · 2022Review
- PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature.Journal of clinical medicine · 2022Review
- Application of PET/CT in Preoperative Evaluation and Diagnosis of Gastric Cancer.Computational and mathematical methods in medicine · 2022Article
- Differences in Distribution and Detection Rate of the [Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PET/CT with prostate-specific membrane antigen (PSMA)-targeted tracers has been used in the diagnosis and staging of patients with clear cell renal cell carcinoma (ccRCC). For ccRCC primary tumors, PET parameters were shown to predict histologic grade and features. The aim of this study was to correlate PSMA PET/CT with histopathological findings in patients with metastatic recurrence of ccRCC. Patients with ccRCC who underwent PSMA-targeted PET/CT and subsequent histopathological evaluation of suspicious lesions were included. Specimens underwent immunohistochemical marking. Lesion diameter, volume and tracer uptake were correlated with the extent and intensity of molecular PSMA expression and with clinical findings. Twelve PET-positive lesions of nine patients were evaluated. Eleven ccRCC metastases and one prostate carcinoma were detected histopathologically. Molecular PSMA expression was detected in all lesions, which intensity and distribution did not correlate with PET parameters. PSMA-targeted PET/CT is a feasible tool for the evaluation of patients with ccRCC but cannot reliably predict histologic features of metastases. PSMA may also be expressed in malignant lesions other than ccRCC, leading to incidental detection of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.